Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Paris – page 202

2 598 clinical trials in Paris, France across 36 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Paris at a glance
2 598
clinical trials
  • Research sites36
Type of trial
Recruitment status
Quick filters

2 598 trials in Paris

Open in trial search

Plasma cell myeloma

Not recruiting

Long-term Safety Study of Daratumumab with Drug Combination for Patients with Multiple Myeloma or Smoldering Multiple Myeloma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Janssen Cilag International

COVID-19

Not recruiting

Study on Antiviral Therapy with Nirmatrelvir and Remdesivir for Immunocompromised COVID-19 Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nirmatrelvir
  • Sponsor:Inserm

T-cell lymphoma

Not recruiting

Study of Tolinapant with Decitabine and Cedazuridine for Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cedazuridine
  • Sponsor:Taiho Oncology Inc.

Hepatocellular carcinoma

Not recruiting

Study of Ezurpimtrostat with Atezolizumab and Bevacizumab for Patients with Unresectable Liver Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Centre Hospitalier Universitaire Grenoble Alpes

Squamous cell carcinoma of head and neck

Not recruiting

Study of Pembrolizumab and Cisplatin for Patients with Stage III-IVA Resectable Head and Neck Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Relapsing-remitting multiple sclerosis

Not recruiting

Study Comparing Rituximab and Ocrelizumab for Patients with Relapsing-Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:Centre Hospitalier Universitaire De Rennes

Axial spondyloarthritis+1

Not recruiting

Study on Upadacitinib for Adults with Active Axial Spondyloarthritis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abt-494
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Plasma cell myeloma

Not recruiting

Study on [68Ga]Ga-PentixaFor for Detecting Multiple Myeloma in Patients Under 66 Eligible for Stem Cell Transplantation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Caffeine
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Cholangitis sclerosing

Not recruiting

Study on the Safety and Tolerability of A3907 for Adults with Primary Sclerosing Cholangitis (PSC)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:A3907
  • Sponsor:Albireo AB

Monkeypox

Not recruiting

Study on Tecovirimat for Treating Monkeypox in Patients with Confirmed Infection

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tecovirimat
  • Sponsor:Universitair Medisch Centrum Utrecht

Sickle cell disease

Not recruiting

Study on the Effect of Famotidine in Reducing P-selectin Levels in Children with Sickle Cell Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Famotidine
  • Sponsor:Assistance Publique Hopitaux De Paris

Mantle cell lymphoma refractory

Not recruiting

Study of BGB-11417 for Patients with Relapsed or Refractory Mantle Cell Lymphoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:N-[4-({[(1R,4R)-4-Hydroxy-4-Methylcyclohexyl]Methyl}Amino)-3- Nitrobenzene-1-Sulfonyl]-4-(2-{(2S)-2-[2-(Propan-2-Yl)Phenyl]Pyrrolidin1-Yl}-7-Azaspiro[3.5]Nonan-7-Yl)-2-[(1H-Pyrrolo[2,3-B]Pyridin-5- Yl)Oxy]Benzamide
  • Sponsor:BeOne Medicines AG

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Paris

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on head and neck squamous cell carcinoma and endometrial cancer, evaluating innovative treatment combinations and survival outcomes.

  • Advanced cancer therapies
  • Combination treatments
  • Survival outcome assessment
02 Metabolic Disorders

Clinical investigations targeting Type 1 Diabetes and obesity, with novel therapeutic approaches using tirzepatide for improved glycemic control.

  • Diabetes management
  • Weight control
  • Metabolic health
03 Infectious Diseases

Innovative vaccine trials for COVID-19, influenza, and cytomegalovirus, exploring both intranasal and injectable delivery methods.

  • Vaccine development
  • Immunogenicity studies
  • Prevention strategies
04 Neurological Conditions

Advanced research in multiple sclerosis and Alzheimer's disease, utilizing cutting-edge imaging techniques to study neuroinflammation and synaptic density.

  • Brain imaging
  • Neurodegenerative diseases
  • Disease progression
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.